AzTrials
AzTrials

Cardio Vascular DiseaseQCRC-AINCT07515807

Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence

An observational study of Cardio Vascular Disease and Acute Coronary Syndromes (ACS), run by Weill Cornell Medical College in Qatar at 1 site in Qatar.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Read more about this study

Who is it for?
Ages 18 years and older
How many people
10,000 participants
Where
1 siteQatar
Study dates
16 Jul 2026to 16 Jul 2030
How long will I take part?
2 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participants admitted at Hamad Medical Corporation for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF).

Who may be able to join

  • Age ≥ 18
  • Qatari and Arab participants
  • Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)
  • Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%

Who cannot join

  • Non-Qatari or non-Arab participants
  • Non-diabetic: HbA1C < 5.7%
  • This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Charbel Abi Khalil Prof contact

+ 974 4492 8484

cha2022@qatar-med.cornell.edu

Qatar1 site

  • Hamad Medical Corporation

    Doha

    Nidal Asaad MD, +974 44390220, nasaad@hamad.qa

Other trials in Qatar

About this study

Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.

Read the detailed description

This study combines retrospective and prospective designs.

Retrospective:

We use past electronic medical records to identify participants and collect baseline information from their initial visit (using their code or health card number).

Prospective:

From that starting point, we follow the same participants forward in time, updating data every two years and recording new outcomes (mortality, cardiovascular events, rehospitalizations, treatment-related outcomes) at planned checkpoints (approximately 6 months, 1 year, and 2 years).

New eligible participants identified in later data extractions are added and followed in the same manner. Because we only observe and record participants existing records and outcomes without assigning interventions, the study is observational.

Medical subject headings
Acute Coronary Syndrome, Diabetes Mellitus, Type 2, Glucose Intolerance

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of 3-point Major Adverse Cardiovascular Events (MACE) in Acute Coronary Syndrome Patients

    Composite endpoint defined as the occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Events will be identified using electronic medical records, hospital admission data, and follow-up assessments during the study period. These outcomes will serve as endpoints for the development and validation of predictive machine learning models.

    Measured: 5 years

  2. Incidences of 2-point Major Adverse Cardiovascular Events (MACE) in Heart Failure Patients

    Composite endpoint defined as cardiovascular death or hospitalization for heart failure. Events will be ascertained through hospital records, clinical documentation, and follow-up data collection. These outcomes will be used as endpoints for predictive model development and validation.

    Measured: 5 years

Secondary outcomes (9)

  1. Major Adverse Cardiovascular Events

    MACE - Major Adverse Cardiovascular Events

    Measured: 5 years

  2. Unstable angina requiring hospitalization

    Measured: 5 years

  3. Arrhythmic events

    Measured: 5 years

  4. Coronary revascularization

    Measured: 5 years

  5. Post-Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG) complications (stent/graft thrombosis or repeat revascularization)

    Measured: 5 years

  6. Development or progression of valvular heart disease (aortic or mitral stenosis/regurgitation)

    Measured: 5 years

  7. New-onset diabetes mellitus

    Measured: 5 years

  8. Change in glycated Hemoglobin A1c (HbA1c)

    Measured: 5 years

  9. Newly diagnosed medical or surgical conditions not present at baseline

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Apr 2026
  2. Study start16 Jul 2026 (estimated)
  3. Primary completion16 Jul 2030 (estimated)
  4. Study completion16 Jul 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
10,000 participants (estimated)
Target duration
2 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07515807
Sponsor's protocol ID
25-00019
Acronym
QCRC-AI
Status last verified
Mar 2026
First submitted
31 Mar 2026
Last updated
21 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Cardio Vascular Disease and Acute Coronary Syndromes (ACS), run by Weill Cornell Medical College in Qatar at 1 site in Qatar.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 21 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Qatar. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Charbel Abi Khalil Prof (+ 974 4492 8484, cha2022@qatar-med.cornell.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of 3-point Major Adverse Cardiovascular Events (MACE) in Acute Coronary Syndrome Patients (time frame: 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07515807.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in